Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6375683 | 0.91 | ECE1 (0.83) | ECE1 | |
| SCHEMBL6375350 | 0.90 | ECE1 (1.00) | ECE1 | |
| SCHEMBL6377620 | 0.88 | ECE1 (1.00) | ECE1 | |
| Hydrochloric Acid SCHEMBL6379247 | 0.88 | ECE1 (0.81) | ECE1 | |
| SCHEMBL7222166 | 0.87 | ECE1 (0.77) | ECE1 | |
| SCHEMBL6382293 | 0.87 | ECE1 (0.80) | ECE1 | |
| SCHEMBL6376927 | 0.86 | ECE1 (0.79) | ECE1 | |
| SCHEMBL6374787 | 0.85 | ECE1 (1.00) | ECE1 | |
| SCHEMBL6375753 | 0.85 | ECE1 (1.00) | ECE1 | |
| SCHEMBL6376933 | 0.84 | ECE1 (0.73) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080104-B1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6689801-B2 | CARDIOVASCULAR DISORDERS; ANTIISCHEMIC AGENTS; HYPOTENSIVE AGENTS; GASTROINTESTINAL DISORDERS | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | disclosed |
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | FINK CYNTHIA ANNE (US) | 2003-01-23 | — | — | US | disclosed |
| US-6426354-B1 | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; BRAIN DISORDERS | NOVARTIS AG (CH) | 2002-07-30 | — | — | US | disclosed |
| EP-1080104-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999055723-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | ECE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.